Blood test and genetic examination show timing in Alzheimer's risk

Examining data from thousands of individuals of diverse ethnic backgrounds, scientists have determined that the combined evaluation of a simple blood test and genetic markers offers crucial clues regarding the timing of cognitive decline linked to Alzheimer's disease.

Scope and Data of the Research

The comprehensive study published in The Lancet Neurology brought together data from seven major studies involving a total of 8,582 individuals from various ethnic backgrounds.

Thanks to this large-scale review, biomarkers and genetic risk factors across different demographic groups were analyzed in detail.

Key Indicators Examined

The two primary biological indicators examined during the research process were blood p-tau217 levels and individuals' APOE genotype.

P-tau217 stands out as a strong blood marker directly associated with amyloid and tau pathology accumulating in the brain during the Alzheimer's process.

The APOE4 genetic variant, on the other hand, ranks among the strongest known genetic risk factors for late-onset Alzheimer's disease.

Cognitive Decline Process and Time Window

According to the findings, as blood p-tau217 levels rise, the likelihood of individuals experiencing cognitive decline in the future also increases.

In individuals carrying at least one copy of APOE4, the window during which cognitive symptoms may emerge following the rise in p-tau217 approaches an average of 3 to 4 years.

It was determined that in individuals with other APOE types, this time window can extend to approximately 5 to 6 years.

Future Treatment Approaches

Scientists who conducted the research emphasize that these findings could greatly help determine the correct treatment window in the future.

The combined use of blood tests and genetic information could open the door to a new era in predicting disease processes.